Compare Stocks: RLAY, ASND, HALO, and BBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$234.33 +1.9%	$243.53	$188.07 ▼ $282.15	$14.34B	0.38	812,958 shs	394,731 shs
BBIO BridgeBio Pharma	$67.55 -0.6%	$72.09	$52.75 ▼ $93.42	$13.21B	0.97	2.84 million shs	2.73 million shs
HALO Halozyme Therapeutics	$124.37 +1.5%	$109.89	$61.22 ▼ $125.10	$13.90B	0.88	2.47 million shs	2.15 million shs
RLAY Relay Therapeutics	$18.45 +8.0%	$18.74	$5.95 ▼ $21.27	$4.04B	1.72	2.91 million shs	1.98 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.90%	+4.98%	-1.01%	-6.99%	+14.19%
BBIO BridgeBio Pharma	-0.57%	+6.71%	+1.41%	-18.28%	+20.07%
HALO Halozyme Therapeutics	+1.53%	+13.46%	+10.60%	+59.82%	+87.11%
RLAY Relay Therapeutics	+7.96%	+6.28%	-2.07%	-4.26%	+158.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$234.33 +1.9%	$243.53	$188.07 ▼ $282.15	$14.34B	0.38	812,958 shs	394,731 shs
BBIO BridgeBio Pharma	$67.55 -0.6%	$72.09	$52.75 ▼ $93.42	$13.21B	0.97	2.84 million shs	2.73 million shs
HALO Halozyme Therapeutics	$124.37 +1.5%	$109.89	$61.22 ▼ $125.10	$13.90B	0.88	2.47 million shs	2.15 million shs
RLAY Relay Therapeutics	$18.45 +8.0%	$18.74	$5.95 ▼ $21.27	$4.04B	1.72	2.91 million shs	1.98 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.90%	+4.98%	-1.01%	-6.99%	+14.19%
BBIO BridgeBio Pharma	-0.57%	+6.71%	+1.41%	-18.28%	+20.07%
HALO Halozyme Therapeutics	+1.53%	+13.46%	+10.60%	+59.82%	+87.11%
RLAY Relay Therapeutics	+7.96%	+6.28%	-2.07%	-4.26%	+158.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$309.26	31.98% Upside
BBIO BridgeBio Pharma	2.88	Moderate Buy	$104.90	55.29% Upside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$99.55	-19.96% Downside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	40.47% Upside

Current Analyst Ratings Breakdown

Latest RLAY, ASND, HALO, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$115.00 ➝ $120.00
10/19/2026	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$94.00 ➝ $91.00
10/16/2026	HALO Halozyme Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$130.00
10/15/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$82.00 ➝ $92.00
10/15/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$307.00 ➝ $269.00
10/14/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/13/2026	ASND Ascendis Pharma A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C)
10/13/2026	HALO Halozyme Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/13/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/8/2026	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$70.00 ➝ $78.00
10/7/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$115.00 ➝ $130.00

(Data available from 10/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	17.95	N/A	N/A	($2.97) per share	-78.90
BBIO BridgeBio Pharma	$713.07M	18.52	N/A	N/A	($10.77) per share	-6.27
HALO Halozyme Therapeutics	$1.40B	10.11	$4.84 per share	25.68	$0.42 per share	296.12
RLAY Relay Therapeutics	$10.35M	390.64	N/A	N/A	$3.27 per share	5.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	18.18	26.18	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	37.13	12.70	0.46	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)

Latest RLAY, ASND, HALO, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ASND Ascendis Pharma A/S	$0.9080	N/A	N/A	N/A	$411.34 million	N/A
11/5/2026	Q3 2026	RLAY Relay Therapeutics	-$0.3964	N/A	N/A	N/A	$1.62 million	N/A
11/2/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	N/A	N/A	N/A	$490.85 million	N/A
10/28/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.5437	N/A	N/A	N/A	$288.74 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
BBIO BridgeBio Pharma	N/A	1.23	1.17
HALO Halozyme Therapeutics	13.50	2.71	2.31
RLAY Relay Therapeutics	N/A	18.27	18.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	99.85%
HALO Halozyme Therapeutics	97.79%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
BBIO BridgeBio Pharma	14.23%
HALO Halozyme Therapeutics	2.50%
RLAY Relay Therapeutics	5.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable

RLAY, ASND, HALO, and BBIO Headlines

Recent News About These Companies

Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.7% - What's Next?

October 20 at 1:19 PM | marketbeat.com

Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs

October 17, 2026 | seekingalpha.com

H.C. Wainwright raises target for Relay Therapeutics stock to USD 29

October 16, 2026 | ad-hoc-news.deA

Relay Therapeutics (NASDAQ:RLAY) CEO Sells $872,401.90 in Stock

October 11, 2026 | defenseworld.netD

Relay Therapeutics (NASDAQ:RLAY) Stock: Insider Thomas Catinazzo Sells 17,717 Shares

October 9, 2026 | insidertrades.com

Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing

October 8, 2026 | marketscreener.comM

Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 17,717 Shares of Company Stock

October 8, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Stock: Insider Sanjiv Patel Sells 48,199 Shares

October 8, 2026 | marketbeat.com

Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value

October 8, 2026 | uk.finance.yahoo.com

Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?

October 8, 2026 | finance.yahoo.com

Congress Asset Management Co. Raises Position in Relay Therapeutics, Inc. $RLAY

October 7, 2026 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 28, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Down 8.8% - What's Next?

September 23, 2026 | marketbeat.com

Relay Therapeutics stock holds near its Nasdaq quote

September 22, 2026 | ad-hoc-news.deA

Bank of America Corp DE Invests $50.42 Million in Relay Therapeutics, Inc. $RLAY

September 21, 2026 | marketbeat.com

Relay Therapeutics stock consolidates after recent gains as investors watch pipeline progress

September 20, 2026 | ad-hoc-news.deA

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

September 10, 2026 | seekingalpha.com

Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 8,530 Shares of Stock

September 10, 2026 | insidertrades.com

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

September 2, 2026 | fool.com

Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats

September 1, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RLAY, ASND, HALO, and BBIO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$234.33 +4.38 (+1.90%)

Closing price 10/20/2026 04:00 PM Eastern

Extended Trading

$236.00 +1.67 (+0.71%)

As of 08:38 AM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma NASDAQ:BBIO

$67.55 -0.39 (-0.57%)

Closing price 10/20/2026 04:00 PM Eastern

Extended Trading

$68.17 +0.62 (+0.92%)

As of 08:56 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics NASDAQ:HALO

$124.37 +1.87 (+1.53%)

Closing price 10/20/2026 04:00 PM Eastern

Extended Trading

$123.54 -0.84 (-0.67%)

As of 08:58 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Relay Therapeutics NASDAQ:RLAY

$18.45 +1.36 (+7.96%)

Closing price 10/20/2026 04:00 PM Eastern

Extended Trading

$18.62 +0.18 (+0.95%)

As of 08:40 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLAY, ASND, HALO, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLAY, ASND, HALO, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLAY, ASND, HALO, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RLAY, ASND, HALO, and BBIO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLAY, ASND, HALO, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLAY, ASND, HALO, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLAY, ASND, HALO, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RLAY, ASND, HALO, and BBIO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools